BRPI0417350A2 - composiÇço para a distribuiÇço nasal, uso de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e quitosana, um sal, um derivado ou sal de um derivado do mesmo, mÉtodos de administraÇço de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e de tratamento ou prevenÇço de nÁusea e/ou vâmito, e, dispositivo para a distribuiÇço da droga nasal ou um cartucho de dose - Google Patents

composiÇço para a distribuiÇço nasal, uso de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e quitosana, um sal, um derivado ou sal de um derivado do mesmo, mÉtodos de administraÇço de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e de tratamento ou prevenÇço de nÁusea e/ou vâmito, e, dispositivo para a distribuiÇço da droga nasal ou um cartucho de dose

Info

Publication number
BRPI0417350A2
BRPI0417350A2 BRPI0417350-3A BRPI0417350A BRPI0417350A2 BR PI0417350 A2 BRPI0417350 A2 BR PI0417350A2 BR PI0417350 A BRPI0417350 A BR PI0417350A BR PI0417350 A2 BRPI0417350 A2 BR PI0417350A2
Authority
BR
Brazil
Prior art keywords
salt
derivative
granisetron
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BRPI0417350-3A
Other languages
English (en)
Inventor
Alan Smith
Peter James Watts
Jonathan Castile
Original Assignee
Archimedes Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archimedes Dev Ltd filed Critical Archimedes Dev Ltd
Publication of BRPI0417350A2 publication Critical patent/BRPI0417350A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSIÇçO PARA A DISTRIBUIÇçO NASAL, USO DE GRAMSETRON OU DE UM SAL FARMACEUTICAMENTE ACEITÁVEL DO MESMO, E QUITOSANA, UM SAL, UM DERIVADO OU UM SAL DE UM DERIVADO DO MESMO, MÉTODOS DE ADMINISTRAÇçO DE GRANISETRON OU DE UM SAL FARMACEUTICAMENTE ACEITÁVEL DO MESMO, E DE TRATAMENTO OU PREVENÇçO DE NÁUSEA E/OU VâMITO, E, DISPOSITIVO PARA A DISTRIBUIÇçO DA DROGA NASAL OU UM CARTUCHO DE DOSE. A presente invenção provê composições para a administração intra-nasal de granisetron ou de um sal farmaceuticamente aceitável do mesmo. Composições preferidas da invenção estão sob a forma de uma solução aquosa. De modo opcional, as composições da invenção compreende quitosano, um sal ou derivado do mesmo ou um sal de um derivado de quitosano. As composições podem ser usadas para o tratamento ou prevenção de náuseas e/ou vômitos.
BRPI0417350-3A 2003-12-05 2004-11-30 composiÇço para a distribuiÇço nasal, uso de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e quitosana, um sal, um derivado ou sal de um derivado do mesmo, mÉtodos de administraÇço de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e de tratamento ou prevenÇço de nÁusea e/ou vâmito, e, dispositivo para a distribuiÇço da droga nasal ou um cartucho de dose BRPI0417350A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0328186.2A GB0328186D0 (en) 2003-12-05 2003-12-05 Intranasal compositions
PCT/GB2004/005043 WO2005056008A1 (en) 2003-12-05 2004-11-30 Intranasal compositions

Publications (1)

Publication Number Publication Date
BRPI0417350A2 true BRPI0417350A2 (pt) 2009-03-10

Family

ID=29764615

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417350-3A BRPI0417350A2 (pt) 2003-12-05 2004-11-30 composiÇço para a distribuiÇço nasal, uso de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e quitosana, um sal, um derivado ou sal de um derivado do mesmo, mÉtodos de administraÇço de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e de tratamento ou prevenÇço de nÁusea e/ou vâmito, e, dispositivo para a distribuiÇço da droga nasal ou um cartucho de dose

Country Status (26)

Country Link
US (1) US7947257B2 (pt)
EP (1) EP1696911B1 (pt)
JP (1) JP5103018B2 (pt)
KR (1) KR101194593B1 (pt)
CN (2) CN102389422A (pt)
AT (1) ATE460932T1 (pt)
AU (1) AU2004296586B2 (pt)
BR (1) BRPI0417350A2 (pt)
CA (1) CA2548559C (pt)
CY (1) CY1110664T1 (pt)
DE (1) DE602004026107D1 (pt)
DK (1) DK1696911T3 (pt)
ES (1) ES2357607T3 (pt)
GB (1) GB0328186D0 (pt)
HR (1) HRP20100343T1 (pt)
IL (1) IL176132A (pt)
ME (1) ME01070B (pt)
MX (1) MXPA06006239A (pt)
NO (1) NO335348B1 (pt)
NZ (1) NZ547848A (pt)
PL (1) PL1696911T3 (pt)
PT (1) PT1696911E (pt)
RS (1) RS51251B (pt)
SI (1) SI1696911T1 (pt)
WO (1) WO2005056008A1 (pt)
ZA (1) ZA200604553B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
CA2519287A1 (en) 2003-03-27 2004-10-14 Bioactis Limited Powder medicine applicator for nasal cavity
US8673360B2 (en) 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
US7868016B2 (en) 2005-07-13 2011-01-11 Baxter International Inc. Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
DE112005003703T5 (de) * 2005-09-23 2008-07-10 Amphenol Phoenix Co., Ltd., Hwaseong Öffnungs- und Schließvorrichtung in Gleitbauweise zur Verwendung in Mobiltelefonen
JP5362360B2 (ja) * 2005-10-11 2013-12-11 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 経鼻投与用組成物
CN101668544B (zh) 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
KR101368587B1 (ko) 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
JP6081102B2 (ja) * 2012-08-10 2017-02-15 テルモ株式会社 安定なグラニセトロン含有水性製剤
US10335398B2 (en) 2015-04-08 2019-07-02 Maxinase Life Sciences Limited Bioadhesive compositions for intranasal administration of granisetron
WO2017123744A1 (en) * 2016-01-12 2017-07-20 Grace Therapeutics Llc Betamethasone oral spray formulation and method of use to treat ataxia
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2004270A1 (en) 1988-12-29 1990-06-29 William R. Michael Perfume microcapsules for use in granular detergent compositions
CA2042529C (en) 1990-08-10 2002-07-30 Chokyun Rha Polysaccharide article and uses therefor
US5929059A (en) 1991-01-19 1999-07-27 Smithkline Beecham P.L.C. Pharmaceutical compositions containing granisetron and dexamethasone
GB9305593D0 (en) 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
HRP950149A2 (en) 1994-04-13 1997-06-30 Janssen Pharmaceutica Nv Intranasal antimigrene composition
GB9414966D0 (en) 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
US20020132803A1 (en) * 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
JP2002255795A (ja) * 2001-02-26 2002-09-11 Teijin Ltd 経鼻投与用組成物
US20030044356A1 (en) * 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
CN1289085C (zh) * 2002-04-26 2006-12-13 中国人民解放军军事医学科学院毒物药物研究所 鼻腔喷雾剂
CN1332664C (zh) * 2002-04-26 2007-08-22 中国人民解放军军事医学科学院毒物药物研究所 鼻粉剂
GB0329918D0 (en) 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions

Also Published As

Publication number Publication date
CN1901905A (zh) 2007-01-24
NO335348B1 (no) 2014-11-24
PL1696911T3 (pl) 2010-08-31
GB0328186D0 (en) 2004-01-07
WO2005056008A1 (en) 2005-06-23
AU2004296586A2 (en) 2005-06-23
CA2548559A1 (en) 2005-06-23
SI1696911T1 (sl) 2010-06-30
CA2548559C (en) 2013-09-03
JP2007513129A (ja) 2007-05-24
RS51251B (sr) 2010-12-31
EP1696911A1 (en) 2006-09-06
CN102389422A (zh) 2012-03-28
JP5103018B2 (ja) 2012-12-19
IL176132A (en) 2010-12-30
EP1696911B1 (en) 2010-03-17
MXPA06006239A (es) 2006-08-23
ATE460932T1 (de) 2010-04-15
KR20060126532A (ko) 2006-12-07
DE602004026107D1 (de) 2010-04-29
AU2004296586A1 (en) 2005-06-23
KR101194593B1 (ko) 2012-10-25
IL176132A0 (en) 2006-10-05
US20050142073A1 (en) 2005-06-30
US7947257B2 (en) 2011-05-24
PT1696911E (pt) 2010-04-29
ZA200604553B (en) 2009-09-30
NO20062548L (no) 2006-08-15
ES2357607T3 (es) 2011-04-28
ME01070B (me) 2012-10-20
NZ547848A (en) 2009-04-30
DK1696911T3 (da) 2010-06-28
HRP20100343T1 (hr) 2010-11-30
CY1110664T1 (el) 2015-06-10
AU2004296586B2 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
NO20062548L (no) Intranasale blandinger
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
WO2007123945A3 (en) Mechanical single dose intrapulmonary drug delivery devices
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
RS52831B (en) THIN BUPRENORPHINE TILES FOR DRUG REPLACEMENT THERAPY
TW200607799A (en) Therapeutic compounds: pyridine as scaffold
AR037629A1 (es) Formulaciones farmaceuticas que comprenden un derivado de platino
TW200500098A (en) Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
WO2006124681A3 (en) Oral drug delivery system and methods of use thereof
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
CL2007000945A1 (es) Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea.
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
TN2010000008A1 (en) Oral pharmaceutical solutions containing telbivudine
AR047346A1 (es) Composicion farmaceutica de vinflunina para administracion parnteral, proceso de preparacion y uso de la misma
WO2004041190A3 (en) Composition for the treatment of macular degenration
BRPI0415651A (pt) métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
HRP20070081T3 (en) Nasal pharmaceutical composition of piribedil
WO2004041181A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 10, 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.